2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol

그림문자(GHS)

• 그림문자(GHS)

  

• 신호 어

  Warning

• 유해·위험 문구

  H410：장기적 영향에 의해 수생생물에 매우 유독함

• 예방조치문구

  P273：환경으로 배출하지 마시오.

  P501：...에 내용물 / 용기를 폐기 하시오.

2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol 화학적 특성, 용도, 생산

• 개요

  In February 2013, the US FDA approved ospemifene (also referred to as FC1271a), for the treatment ofmoderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA), due tomenopause. It is estimated that there are 150 million postmenopausal women worldwide with 40–70% suffering from VVA. Ospemifene is a selective estrogen receptor (ER) modulator (SERM) and the first nonhormonal, nonestrogen for the treatment of moderate to severe dyspareunia in women with menopausal VVA. It binds to ERα (IC₅₀～800 nM) and ERβ (IC₅₀～1600 nM) with tissue-specific estrogenic agonist/antagonist effects. Treatment with ospemifene increases the thickness of the vaginal tissue thereby decreasing fragility of the tissue and reducing potential for pain during sexual intercourse.

• 용도

  Treatment of vaginal atrophy, osteoporosis, and vasomotor symptoms.

• 정의

  ChEBI: An organochlorine compound that is a selective estrogen receptor modulator; used for treatment of dyspareunia.

• Clinical Use

  Ospemifene is a SERM that is currently in Phase II/III clinical trials for the treatment of postmenopausal osteoporosis and urogenital atrophy. It is a known metabolite of toremifene, a triphenylethylene derivative used to treat breast cancer.Ospemifene has been shown to have beneficial effects on the bone without significant estrogen-related side effects. The beneficial effect observed on bone stems from this agent's ability to increase osteoblast proliferation and, as a result, to enhance bone mineralization as well as bone formation. Unlike tamoxifen, ospemifene does not induce osteocyte apoptosis.

2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol 공급 업체

Global(154)Suppliers

2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol 관련 검색